Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
11
|
| pubmed:dateCreated |
1998-6-11
|
| pubmed:abstractText |
Previously we demonstrated that 1,25-dihydroxyvitamin D3 blocks the progression of relapsing encephalomyelitis. We now propose that 1,25-dihydroxyvitamin D3 blocks these autoimmune symptoms by stimulating the differentiation and/or function of cells that inhibit the encephalitogenic process. To support this belief, we have found that 1,25-dihydroxyvitamin D3 administration to mice increases IL-4 transcripts by 3- to 25-fold and TGF-beta 1 transcripts by 4- to 24-fold. Similarly, IL-4 and TGF-beta 1 transcripts were higher in the central nervous system of 1,25-dihydroxyvitamin D3-treated mice compared with controls. The number of cells recoverable from the lymph nodes of 1,25-dihydroxyvitamin D3-treated mice was only 50% that of controls. Overall, 1,25-dihydroxyvitamin D3 treatment causes a net loss in the total number of lymphocytes while the number of IL-4 and TGF-beta 1 transcripts increased. The systemic and local increase in the expression of these two anti-inflammatory cytokines by 1,25-dihydroxyvitamin D3 may be responsible for the ability of this drug to block encephalomyelitis.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adjuvants, Immunologic,
http://linkedlifedata.com/resource/pubmed/chemical/Calcitriol,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-gamma,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-4,
http://linkedlifedata.com/resource/pubmed/chemical/Transforming Growth Factor beta,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
0022-1767
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
1
|
| pubmed:volume |
160
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
5314-9
|
| pubmed:dateRevised |
2008-11-21
|
| pubmed:meshHeading |
pubmed-meshheading:9605130-Adjuvants, Immunologic,
pubmed-meshheading:9605130-Administration, Oral,
pubmed-meshheading:9605130-Animals,
pubmed-meshheading:9605130-Calcitriol,
pubmed-meshheading:9605130-Cells, Cultured,
pubmed-meshheading:9605130-Encephalomyelitis, Autoimmune, Experimental,
pubmed-meshheading:9605130-Female,
pubmed-meshheading:9605130-Interferon-gamma,
pubmed-meshheading:9605130-Interleukin-4,
pubmed-meshheading:9605130-Lymph Nodes,
pubmed-meshheading:9605130-Lymphocyte Count,
pubmed-meshheading:9605130-Male,
pubmed-meshheading:9605130-Mice,
pubmed-meshheading:9605130-Mice, Inbred C57BL,
pubmed-meshheading:9605130-Spinal Cord,
pubmed-meshheading:9605130-Transcription, Genetic,
pubmed-meshheading:9605130-Transforming Growth Factor beta,
pubmed-meshheading:9605130-Tumor Necrosis Factor-alpha
|
| pubmed:year |
1998
|
| pubmed:articleTitle |
1,25-dihydroxyvitamin D3 is a positive regulator for the two anti-encephalitogenic cytokines TGF-beta 1 and IL-4.
|
| pubmed:affiliation |
Department of Biochemistry, University of Wisconsin-Madison, College of Agricultural and Life Sciences 53706, USA.
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|